Aytu BioScience, Inc., a specialty healthcare company, focuses on developing and commercializing novel products in the field of urology in the United States. The company markets Natesto for the treatment of hypogonadism (low testosterone) in men; and ProstaScint for use in newly diagnosed high-risk prostate cancer patients and patients with recurrent prostate cancer. It is also involved in commercializing of the RedoxSYS System for research use in various applications. In addition, the company is developing MiOXSYS, an in vitro diagnostic semen analysis test that is used in the quantitative measurement of static oxidation reduction potential in human semen. Further, the company provides Fiera personal care device, a hands-free wearable product for women that is designed to enhance interest in and physical readiness for sex. Aytu BioScience, Inc. is based in Englewood, Colorado.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AYTU
CUSIPN/A
Phone720-437-6580
Debt
Debt-to-Equity RatioN/A
Current Ratio3.36
Quick Ratio3.16
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$3.22 million
Price / Sales0.58
Cash FlowN/A
Price / CashN/A
Book Value$4.84 per share
Price / Book0.07
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-22,500,000.00
Net Margins-385.77%
Return on Equity-257.49%
Return on Assets-85.73%
Miscellaneous
Employees63
Outstanding Shares5,600,000
Aytu Bioscience (NASDAQ:AYTU) Frequently Asked Questions
What is Aytu Bioscience's stock symbol?
Aytu Bioscience trades on the NASDAQ under the ticker symbol "AYTU."
When did Aytu Bioscience's stock split? How did Aytu Bioscience's stock split work?
Aytu Bioscience's stock reverse split before market open on Tuesday, August 29th 2017. The 1-20 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 28th 2017. An investor that had 100 shares of Aytu Bioscience stock prior to the reverse split would have 5 shares after the split.
How were Aytu Bioscience's earnings last quarter?
Aytu Bioscience Inc (NASDAQ:AYTU) issued its earnings results on Friday, February, 9th. The company reported ($0.89) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($1.78) by $0.89. The company earned $1.05 million during the quarter. Aytu Bioscience had a negative net margin of 385.77% and a negative return on equity of 257.49%. View Aytu Bioscience's Earnings History.
What price target have analysts set for AYTU?
1 brokers have issued 1 year price targets for Aytu Bioscience's shares. Their forecasts range from $3.00 to $3.00. On average, they expect Aytu Bioscience's share price to reach $3.00 in the next twelve months. View Analyst Ratings for Aytu Bioscience.
Who are some of Aytu Bioscience's key competitors?
Some companies that are related to Aytu Bioscience include Immune Pharmaceuticals (IMNP), Boston Therapeutics (BTHE), Biostar Pharmaceuticals (BSPM), Cotinga Pharmaceuticals (COTQF), Bioblast Pharma (ORPN), Amarillo Biosciences (AMAR), Stellar Biotechnologies (SBOT), Auris Medical (EARS), Praxsyn (PXYN), Parnell Pharmaceuticals (PARNF), Orexigen Therapeutics (OREX), Aoxing Pharmaceutical (AOXG), Integrated BioPharma (INBP), iCo Therapeutics (ICOTF) and GlobeImmune (GBIM).
Who are Aytu Bioscience's key executives?
Aytu Bioscience's management team includes the folowing people:
- Mr. Joshua R. Disbrow, Chairman, CEO & Pres (Age 43)
- Mr. Jarrett T. Disbrow Ph.D., Chief Operating Officer (Age 43)
- Mr. David A. Green, CFO, Sec. & Treasurer (Age 55)
Has Aytu Bioscience been receiving favorable news coverage?
News stories about AYTU stock have been trending positive this week, Accern Sentiment reports. The research group identifies negative and positive media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Aytu Bioscience earned a daily sentiment score of 0.25 on Accern's scale. They also gave media headlines about the company an impact score of 47.24 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.
Who are Aytu Bioscience's major shareholders?
Aytu Bioscience's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Highbridge Capital Management LLC (19.09%), MCF Advisors LLC (6.38%) and K.J. Harrison & Partners Inc (3.61%). Company insiders that own Aytu Bioscience stock include David A Green and Jarrett Disbrow. View Institutional Ownership Trends for Aytu Bioscience.
Which major investors are buying Aytu Bioscience stock?
AYTU stock was acquired by a variety of institutional investors in the last quarter, including Highbridge Capital Management LLC, MCF Advisors LLC and K.J. Harrison & Partners Inc. Company insiders that have bought Aytu Bioscience stock in the last two years include David A Green and Jarrett Disbrow. View Insider Buying and Selling for Aytu Bioscience.
How do I buy shares of Aytu Bioscience?
Shares of AYTU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aytu Bioscience's stock price today?
One share of AYTU stock can currently be purchased for approximately $0.3311.
How big of a company is Aytu Bioscience?
Aytu Bioscience has a market capitalization of $1.86 million and generates $3.22 million in revenue each year. Aytu Bioscience employs 63 workers across the globe.
How can I contact Aytu Bioscience?
Aytu Bioscience's mailing address is 373 INVERNESS PARKWAY SUITE 206, ENGLEWOOD CO, 80112. The company can be reached via phone at 720-437-6580 or via email at [email protected]
MarketBeat Community Rating for Aytu Bioscience (AYTU)
MarketBeat's community ratings are surveys of what our community members think about Aytu Bioscience and other stocks. Vote "Outperform" if you believe AYTU will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AYTU will underperform the S&P 500 over the long term. You may vote once every thirty days.
